Patients receiving IFN-α therapy for hepatitis C also have elevated levels of endothelin-1 (ET-1), a key mediator involved in the pathogenesis of PAH, and ET-1 can be induced by interferon in vascular smooth muscle [95]. Here, EDN1 is linked to pulmonary arterial hypertension.